Bayer to Feature Prostate Cancer Research at ASCO GU 2018 Symposium

Truckee, CA (UroToday.com) Bayer announced that research on radium Ra 223 dichloride injection and darolutamide, the company's investigational oral androgen receptor (AR) antagonist, in prostate cancer will be presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 8-10 in San Francisco.

Bayer will present data from the first interim analysis of REASSURE, a real-world, observational study to assess the safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. In addition, efficacy and safety data from an international, open-label study in mCRPC patients who were re-treated with radium-223 will be presented. Bayer will also present on darolutamide, including the ARASENS pivotal trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).

"We look forward to presenting analyses on the long-term efficacy and safety of radium-223 and data on our investigational compound darolutamide at this year's ASCO GU Symposium," said Scott Fields, MD, Bayer's senior vice president and head of Pharmaceutical Development, Oncology. "We are committed to the prostate cancer community and to Bayer's critical mission of serving those patients with the greatest unmet needs."
Notable radium-223 and darolutamide studies to be presented at the ASCO GU 2018 Symposium include the following:

Radium-223 Dichloride (radium-223)
  • Radium-223 retreatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up
  • Abstract 178, BOARD H18, Poster Session A: Prostate Cancer and Trials in Progress
  • Date: Thursday, February 8: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM
  • Location: Level 1, West Hall
  • First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of U.S. patients (Pts) by prior/concomitant treatment (Tx)
  • Abstract 233, BOARD L9, Poster Session A: Prostate Cancer and Trials in Progress
  • Date: Thursday, February 8: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM
  • Location: Level 1, West Hall
Darolutamide
  • ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)
  • Abstract TPS383, BOARD P1, Poster Session A: Prostate Cancer and Trials in Progress
  • Date: Thursday, February 8: 11:30 AM-1:00 PM and 5:15 PM-6:15 PM
  • Location: Level 1, West Hall
  • Blood Brain Barrier Penetration of [14C] Darolutamide Compared with [14C] Enzalutamide in Rats Using Whole Body Autoradiography
  • Abstract 345, BOARD D14, Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers and Trials in Progress
  • Date: Friday, February 9: 12:15 PM-1:45 PM and 6:00 PM-7:00 PM
  • Location: Level 1, West Hall
General Castration-resistant Prostate Cancer (CRPC)
  • Survival outcomes of pre-metastatic castration-resistant prostate cancer and the burden of developing metastasis: A systematic literature review
  • Abstract 293, BOARD B4, Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers and Trials in Progress
  • Date: Friday, February 9: 12:15 PM-1:45 PM and 6:00 PM-7:00 PM
  • Location: Level 1, West Hall
email news signup